RT Journal Article
SR Electronic
T1 Predictive performance of international COVID-19 mortality forecasting models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20151233
DO 10.1101/2020.07.13.20151233
A1 Friedman, Joseph
A1 Liu, Patrick
A1 Troeger, Christopher E.
A1 Carter, Austin
A1 Reiner, Robert C.
A1 Barber, Ryan M.
A1 Collins, James
A1 Lim, Stephen S.
A1 Pigott, David M.
A1 Vos, Theo
A1 Hay, Simon I.
A1 Murray, Christopher J.L.
A1 Gakidou, Emmanuela
YR 2020
UL http://medrxiv.org/content/early/2020/11/19/2020.07.13.20151233.abstract
AB Forecasts and alternative scenarios of COVID-19 mortality have been critical inputs into a range of policies and decision-makers need information about predictive performance. We identified n=386 public COVID-19 forecasting models and included n=8 that were global in scope and provided public, date-versioned forecasts. For each, we examined the median absolute percent error (MAPE) compared to subsequently observed mortality trends, stratified by weeks of extrapolation, world region, and month of model estimation. Models were also assessed for ability to predict the timing of peak daily mortality. The MAPE among models released in July rose from 1.8% at one week of extrapolation to 24.6% at twelve weeks. The MAPE at six weeks were the highest in Sub-Saharan Africa (34.8%), and the lowest in high-income countries (6.3%). At the global level, several models had about 10% MAPE at six weeks, showing surprisingly good performance despite the complexities of modelling human behavioural responses and government interventions. The framework and publicly available codebase presented here (https://github.com/pyliu47/covidcompare) can be routinely used to compare predictions and evaluate predictive performance in an ongoing fashion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was primarily supported by the Bill & Melinda Gates Foundation. J.F. received support from the UCLA Medical Scientist Training program (NIH NIGMS training grant GM008042).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was deemed exempt from review by the University of Washington Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code for this analysis are available at: https://github.com/pyliu47/covidcompare https://github.com/pyliu47/covidcompare